BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that it has been awarded one of this year's Nordic Stars Awards at the Nordic Life Science Days 2015 conference held in Stockholm, Sweden on 9-10 September, 2015.
BerGenBio has been presented with this award in recognition of its market-leading innovation and entrepreneurial skills in the Nordic life science community.
On news of this award, Richard Godfrey, Chief Executive Officer of BerGenBio, commented:
"This is an exciting time for us at BerGenBio. We are making significant progress with BGB324, our first-in-class selective Axl inhibitor. We are proud to be honoured with this award as we continue to grow and establish ourselves as a leader in the development of innovative drugs for aggressive cancers."
Jonas Ekstrand, Director General SwedenBIO, organisers of the Nordic Stars Awards, said: "BerGenBio's deep biological understanding of epithelial-mesenchymal transition (EMT), immune evasion and metastasis makes them a worthy winner of this year's award. With its focus on ground‐breaking therapies and precision medicine, BerGenBio is a leading example and a Nordic Star."
AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology